$OCGN I've been holding a lot of shares here since 2018. ... I understand Covaxin has several biotechnological advantages compared with other current vaccines in the U.S. However, in a politically disadvantageous situation, I’m wondering whether Indian vaccine, Covaxin will be able to get into the US vaccine market which has seemingly sufficient supplies of vaccines even when it gets P3’s good efficacy results and the FDA approval. I would like somebody here to reasonably explain how Covaxin will become commercially successful in the U.S. and OCGN’s sp will be much higher ($30-60 and 100+?). Please refrain from giving any emotional and groundless prospect. I’ll stay reasonably optimistic.
11
3
3 Likes